Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriation moves to committee

This article was originally published in The Tan Sheet

Executive Summary

A House Appropriations subcommittee approves funding for FDA that matches the Obama administration's fiscal 2010 FDA budget request of $2.35 billion in direct appropriations, a 14.6 percent increase over the fiscal 2009 level. During a June 11 markup on appropriations for the Department of Agriculture and FDA, Subcommittee Chairwoman Rosa DeLauro, D-Conn., noted that with user fees, FDA's appropriation increases $373 million to almost $3 billion, which "will help to reform and significantly improve how the agency ensures food and medical product safety" (1"The Tan Sheet" May 25, 2009, p. 3). Appropriations Chairman David Obey, D-Wis., scheduled the USDA and FDA appropriation markup for June 18

You may also be interested in...



Sharfstein Defends FDA User Fees As Key To A New Food Safety System

The $215.4 million increase in user fees requested under FDA's fiscal 2010 budget is backed by the Obama administration and will provide key funding to drive change at the agency, particularly in the food safety arena, Josh Sharfstein said

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS103011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel